Aleks

Passionate about speeding innovation to patients. #SarcomaAwareness🎗 Scientist, entrepreneur, Latino-Slavic-American 🇨🇱 🇷🇸 🇺🇸

[Bruce Booth @LifeSciVC]

Drug spending isn't the driver of increasing healthcare costs in any OECD country. Drug spend grew slowly for 25 years (yellow line), while overall healthcare spending outpaces it (blue line).

New IQVIA report: https://t.co/eCbEGdVBfe

[Be Biopharma @bebiopharma]

We are excited to announce the first participant treated with BE-101 in the BeCoMe-9 Phase 1/2 clinical trial! BE-101 is our first BCM to enter the clinic, and holds the promise of transforming the hemophilia B treatment landscape. Read the full release: https://t.co/8LgaySQg8I

[Newleos Therapeutics @NewleosTx]

We launched today w/ a $93.5M Series A and a clinical-stage pipeline licensed from @Roche to transform the treatment of #neuropsychiatric disorders. @GoldmanSachs Alternatives led w/ @novoholdings A/S, @LongwoodFund, @DCVCBio, & Arkin Holdings. https://t.co/mD0GOKPTVF

[Endpoints News @endpts]

Start-up Newleos emerges with $93.5m raised and a series of experimental CNS drugs from Roche.
https://t.co/Rzov3w2mCx

[Aleks @aradovicm]

Awesome to have Melissa @NextechInvest aboard for this critical part of the journey

[Be Biopharma @bebiopharma]

We are excited to announce the closing of our $92M series C financing! This milestone will enhance our efforts in advancing BE-101 for Hemophilia B through clinical proof of concept and progress BE-102 for Hypophosphatasia to the clinic. https://t.co/I9QtaY1F01

[Be Biopharma @bebiopharma]

We are excited to announce the closing of our $92M series C financing! This milestone will enhance our efforts in advancing BE-101 for Hemophilia B through clinical proof of concept and progress BE-102 for Hypophosphatasia to the clinic. https://t.co/I9QtaY1F01

[Longwood Healthcare Leaders @LongwoodLeaders]

Thank you @docrodwong @RtwLp @Mpmcapital @engineventures @Jeito_life @aradovicm @LongwoodFund for sharing your insightful #investorperspectives #longwoodhealthcareleaders
#SanFranciscoCEO

[Aleks @aradovicm]

Wow a positive (?) note from @adamfeuerstein ! My life has peaked? 😆

[Adam Feuerstein ✡️ @adamfeuerstein]

@avidresearch $VOR is really interesting.

[Aleks @aradovicm]

@jrkelly Safe & effective delivery systems for nucleic acids and proteins that reach any/all tissues/cells of interest. Or clever workarounds. Solve delivery and R&D success will be transformed 🙌

[Longwood Healthcare Leaders @LongwoodLeaders]

A fantastic end to the day hearing investor perspectives on the environment. Thank you @citi @MPMCapital @JPMorganAM @LongwoodFund @aradovicm

[Aleks @aradovicm]

Discussing investor perspectives in election season this coming Tuesday w/ tremendous panelists: Ansbert Gadicke (MPM), Claudine Prowse (JPM), Dean Dimizas (Cambridge Assoc), and Yigal Nochomovitz (Citi) 😊

[Jonathan Gootenberg @jgooten]

How can AI change biological research?

In a new perspective, we (+@omarabudayyeh ) cover the potential for revolutions, ranging from proteins to (virtual) cells. @naturemethods

https://t.co/V996l6bsQf

1/x

[Aleks @aradovicm]

Cool work @seattlechildren et al - using plasma cells (PC) that secrete bispecific antibodies to treat cancer. Because the PCs home to bone marrow, the local effects are pronounced. PCs can engraft in marrow without toxic conditioning & can be redosed, offering many advantages

[Be Biopharma @bebiopharma]

We’re excited to announce that we’ve been published in the journal Molecular Therapy. The article written in collaboration with our founders at SCRI, covers an oncology application. Read it here: https://t.co/yDho1FmTSg. #BeBio #Oncology

[Aleks @aradovicm]

Nice pun

[Nature Biotechnology @NatureBiotech]

Companies are engineering B cells to produce gene-encoded medicines, but clinical proof of concept is needed to convince the doubters that this platform can deliver https://t.co/M25tCz0gDE

[Be Biopharma @bebiopharma]

Thrilled to announce the clearance of our IND from the FDA for BE-101 for the potential treatment of hemophilia B. We expect to initiate a Phase 1/2 study, BeCoMe-9, in the 2nd half of 2024. Full release here: https://t.co/woA8VzTSEc #BCell #BeBold #BCellMedicines #BCMs

[Longwood Fund @LongwoodFund]

Congratulations to @LongwoodFund portfolio company @bebiopharma on the IND clearance from @US_FDA! Onwards to help patients #hemophilia

Read the release: https://t.co/dWk8pcRKHf

[Longwood Fund @LongwoodFund]

We're thrilled to announce the latest Longwood portfolio company, Progentos Therapeutics. Congratulations on the Series A! #multiplesclerosis #regenerativemedicine

Read the release: https://t.co/adqr4X7TDv

[Be Biopharma @bebiopharma]

Be Bio will present new preclinical data highlighting our novel approach using engineered B-cell Medicines (BCMs) as a potential new treatment for Hypophosphatasia (HPP) at the @ASGCTherapy 27th Annual Meeting. Full release here: https://t.co/U9trDlJKTw. #ASGCT24

[Longwood Fund @LongwoodFund]

We're thrilled to share the news on our latest investment, Engrail Therapeutics https://t.co/HI74MaMNLz

Read the release here: https://t.co/0WHf4j4bU2